Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HFK2
- Development stage
- Unknown
- Lead developer
- HighField Biopharmaceuticals
- Modality
- Small Molecules, Antibody-Based Therapeutics, Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
HFK2 is an immunoliposome developed by HighField Biopharmaceuticals as a targeted cancer therapy. It is part of the company's proprietary ADCplex™ platform. HFK2 is designed to deliver a chemotherapy payload that inhibits Topoisomerase II activity. It is conjugated with HER2 antibodies, enabling it to bind to HER2 receptors on cancer cell surfaces, including both HER2 high and low tumors. HFK2 is being investigated for its potential in treating solid tumors, particularly in combination with HF158K1. Preclinical studies have shown promising efficacy and a wider therapeutic window compared to existing antibody-drug conjugates targeting HER2.
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HFK2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HFK2.